VIEWRAY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000138 USD | +13,700.00% |
|
0.00% | 0.00% |
| 11/04 | North American Morning Briefing : Stock Futures -2- | DJ |
| 12/03 | Cowealth Medical China Gets Business Authorization for ViewRay Systems' Products | MT |
| Sales 2021 | 70.12M 5.85B | Sales 2022 | 102M 8.52B | Capitalization | 813M 67.79B |
|---|---|---|---|---|---|
| Net income 2021 | -110M -9.17B | Net income 2022 | -107M -8.92B | EV / Sales 2021 | 11.8 x |
| Net cash position 2021 | 150M 12.55B | Net cash position 2022 | 49.56M 4.13B | EV / Sales 2022 | 7.47 x |
| P/E ratio 2021 |
-8.24
x | P/E ratio 2022 |
-7.54
x | Employees | 295 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on ViewRay, Inc.
More recommendations
More press releases
| 1 day | +13,700.00% |
1 week
0.00
0.00
1 month
0.000.00
Current year
0.000.00
1 year
0.001.21
3 years
0.008.25
5 years
0.009.76
10 years
0.0013.21
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Ziegler
CEO | Chief Executive Officer | 52 | 01/19/01 |
James F. Dempsey
FOU | Founder | 53 | 01/04/01 |
Cassie Mahar
DFI | Director of Finance/CFO | 38 | 01/19/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Karen Prange
BRD | Director/Board Member | 60 | 11/21/11 |
B. Johnson
BRD | Director/Board Member | 72 | 14/20/14 |
Caley Castelein
BRD | Director/Board Member | 53 | 01/08/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.24% | 16 M€ | -7.06% | ||
| 0.02% | 509 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/24/25 | 0.000138 | +13,700.00% | 184 |
| 24/24/24 | 0.000001 | 0.00% | 2,600 |
Delayed Quote OTC Markets, April 25, 2024 at 08:53 pm IST
More quotes
ViewRay, Inc. is engaged in designing, manufacturing, and marketing the MRIdian MRI-Guided Radiation Therapy System. The MRIdian MR-Guided Radiation Therapy System integrates diagnostic MR imaging with radiation therapy delivery to enable on-table adaptive treatments with real-time tissue tracking and automatic beam gating. The MRIdian is comprised of three components, namely magnetic resonance imaging (MRI) system, radiation delivery system, and integrated treatment planning and delivery software. MRIdian employs MRI-based technology to provide real-time imaging that targets tumors from the surrounding soft tissue and other critical organs, both before and during radiation treatment delivery. MRIdian offers MR-guided imaging that provides tissue visualization compared to cone-beam computed tomography (CBCT), to enable contouring and reduced margins. The Company has installed approximately 56 MRIdian systems at hospitals, which are used to treat a variety of solid tumors.
Calendar
02/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 25.31K | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +1.67% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- VRAYQ Stock
